ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 /uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to ...

Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in ...

Brain Tumours, particularly malignant types such as glioblastoma multiforme (GBM), continue to pose a significant clinical ...

SAN DIEGO, June 11, 2025--iXCells Biotechnologies USA, Inc. ("iXCells"), a leading cell technology company specializing in ...

Koby Baranes, PhD, head of science at Clock Bio, cautions, “Aging is not yet fully understood and existing models often fail ...

XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with ...

The approval of XellSmart's clinical trial, along with the special exemption granted, signifies the FDA's recognition of XellSmart's well-established clinical-grade iPSC-derived cell drug ...

In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, received FDA approval and was granted global orphan drug designation (ODD). In 2024, the world's first ...